Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Non-profit
  • Arts
  • Education
  • Technology
  • Books
ncarol.com

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
ncarol.com/10174305

Trending...
  • SPJ's Green Eyeshade Awards Journalism Competition, Celebrating 75 Years, Announces 2025 Honors
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial hypertension ("PAH").

Tenax Therapeutics' efforts to optimize its formulation of imatinib mesylate, TNX-201, have culminated in a modified release tablet that effectively minimizes gastric release while preserving bioavailability. The pharmacokinetic data from this trial showed that TNX-201 significantly exceeded Tenax' relative bioavailability threshold (area under the curve (AUC)) when compared to reference Gleevec® tablets. These pharmacokinetic results are consistent with earlier in vitro dissolution data that indicated the formulation should limit gastric release while optimizing intestinal absorption.

"Since it has been established that oral imatinib is effective in PAH, our goal has been to modify the dissolution characteristics so as to mitigate the GI side effects and improve adherence to the effective dose," said Stuart Rich MD, Chief Medical Officer of Tenax Therapeutics. "We are optimistic that we now have a product that will serve the needs of our patients with PAH better than before."

Based on these positive pharmacokinetic findings, Tenax Therapeutics and its formulation partner are now manufacturing TNX-201 at the target scale for both the Phase 3 trial and future market demand.

"We believe that the TNX-201 modified release formulation will optimize imatinib blood levels while limiting gastric release and related gastric side effects for patients receiving TNX-201 in our Phase 3 trial," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "Having determined the formulation and moved into the site selection stage of IMPROVE, we are closer than ever to unlocking imatinib's potential to change the lives of patients with PAH."

IMPROVE is the Phase 3 clinical trial of imatinib for PAH sponsored by Tenax Therapeutics. Clinical sites are now being recruited, with patient enrolment expected to start in 2H 2022.

About Tenax Therapeutics

More on ncarol.com
  • Rent Like A Champion Acquires CollegeWeekends
  • First Flight Society Celebrates National Aviation Day 2025 on Tuesday, August 19th
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • Free Marketing Book Saves Brands from Being Ignored

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has world-class scientific advisory teams, including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize subcutaneous and oral formulations of levosimendan and has recently released detailed results from the Phase 2 HELP Study of levosimendan in Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting, and in the Journal of the American College of Cardiology: Heart Failure. Tenax Therapeutics is also developing a unique oral formulation of imatinib designed to minimize the gastric irritation observed in a previous Phase 3 trial of the marketed version of the therapy while assuring that the dose achieved is at the level necessary for the drug to be effective. Tenax Therapeutics expects to conduct a single pivotal trial pursuant to the 505(b)(2) pathway for regulatory approval. For more information, visit www.tenaxthera.com .

About Imatinib (TNX-201)

Tenax Therapeutics is developing novel dosing and a unique formulation of imatinib mesylate, a kinase inhibitor that has received FDA's orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH). The IMPRES trial, a previous Phase 3 trial, demonstrated that oral imatinib may produce a markedly greater, and much more durable, treatment effect on exercise tolerance, than any other available PAH treatment, alone or in combination, in those patients who were maintained on the full imatinib dose for the majority of the trial. Despite the availability of several classes of pulmonary vasodilators, no existing treatment has been shown to halt progression or induce regression of the disease. Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. Tenax Therapeutics intends to commence a Phase 3 trial of TNX-201 in 2H 2022.

More on ncarol.com
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
  • Nonprofit innovator named Mensa Executive Director

About Levosimendan (TNX-102 and TNX-103)

Levosimendan is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action. Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in over 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Tenax Therapeutics has North American rights to develop and commercialize oral (TNX-103) and subcutaneous (TNX-102) formulations of levosimendan. Results of Tenax Therapeutics' Phase 2 trial of levosimendan in patients with pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) demonstrated that IV levosimendan produces potent dilation of the central and pulmonary venous circulations which translates into an improvement in exercise capacity. Patients have now completed the open-label transition study from weekly IV to a more convenient daily, oral regimen, TNX-103. The discovery that venous dilation of the splanchnic circulation with levosimendan leads to increased exercise capacity in PH-HFpEF patients forms the basis for the Phase 3 investigation of Tenax Therapeutics' potential groundbreaking therapy. To date, no other drug therapy has improved exercise tolerance in patients with PH associated with HFpEF, recently referred to as the greatest unmet need in cardiovascular disease.

Caution Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing and customer acceptance of our product candidates; intellectual property risks; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including on our Board of Directors; volatility and uncertainty in the global economy and financial markets in light of the evolving COVID-19 pandemic and geopolitical uncertainties such as in Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.

Contacts

Investor Contact:
John Mullaly
Managing Director
LifeSci Advisors, LLC
C: 617-429-3548
jmullaly@lifesciadvisors.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Ironside HR Named Fastest-Growing Staffing Firm for Second Year
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • Duke Energy announces dividend payments to shareholders
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Financial Educator Nadia Vanderhall Featured On GMA To Share Real-Life Budgeting Insights
  • Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
  • The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • Secrets in the Himalayas: Author K.A. Nayampalli Comes to Barnes & Noble Huntersville
  • Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
_catLbl0 _catLbl1

Popular on ncarol.com

  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart - 110
  • Jeopardy!'s Ken Jennings Headlines National Mensa Event - 108
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook - 103
  • Mensa Foundation Prize Awarded to Neuroscientist-Pianist - 103
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly

Similar on ncarol.com

  • Pixel Studio Productions Launches Same-Day Headshots in Houston
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • Nonprofit innovator named Mensa Executive Director
  • Yasmine Roulleau named Managing Director in Vancouver, Canada
  • Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
  • Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute